河喜多 智美 (カワキタ トモミ)

総合イノベーション創発機構ワクチン研究開発拠点特任助教

研究者基本情報

■ 学位
  • 医学博士, 横浜市立大学, 2021年03月
■ URL
researchmap URLホームページURL■ ID 各種
ORCID IDJ-Global ID

研究活動情報

■ 論文
  • Lipid nanoparticle-encapsulated microRNA-192: An anti-inflammatory adjuvant that enhances vaccine efficacy in aged mice
    Yuriko Takagi; Tasuku Nishimura; Suraiya Aktar; Daisuke Katayama; Ken Takashima; Tomomi Kawakita; Toshiki Sekiya; Masashi Shingai; Hiroki Tanaka; Hidetaka Akita; Yusuke Miyashita; Kimitoshi Nakamura; Takahisa Kouwaki; Hiroyuki Oshiumi
    Molecular Therapy Nucleic Acids, 2026年03月
    英語, 研究論文(学術雑誌)
  • A Case of Infection with Leptospires from Three Different Serovars During a Flood in the Philippines
    Yasutake Yanagihara; Toshiyuki Masuzawa; Masashi Shingai; Marumi Ohno; Toshiki Sekiya; Naoki Nomura; Tomomi Kawakita; Chimuka Handabile; Yuichi Koshiishi; Richard Obeng-Kyeremeh; Toshihiro Ito; Mitsumasa Saito; Sharon Y. A. M. Villanueva; Nina G. Gloriani; Hiroshi Kida
    The American Journal of Tropical Medicine and Hygiene, 2025年09月03日
    研究論文(学術雑誌), ABSTRACT.
    Leptospirosis a significant and life-threatening zoonosis with global reach. If diagnosis and treatment are delayed, the infection may lead to fatal Weil’s disease. In the Philippines, a 21-year-old man was admitted to the hospital with leptospirosis-like symptoms, including fever, myalgia, headache, anuria, jaundice, hemorrhage, skin rash, and diarrhea. Although he was immediately treated with penicillin G, the patient died shortly after admission. The serological test result was negative for Leptospira; however, three leptospires were isolated from the patient through selective cultivation under varying conditions. Microscopic agglutination tests and a phylogenetic analysis of the flaB gene encoding the flagellin subunit protein revealed that the isolates belonged to three different serovars, suggesting that the patient was simultaneously infected with at least three distinct Leptospira serovars. In this case report, we highlight the potential risk of multiple infections with leptospires in humans, a critical consideration for diagnosis and treatment strategies.
  • ARNAX, but not conventional adjuvants, alum and squalene, induces antigen-specific CD8+ T cell proliferation in vaccination with influenza split vaccine
    Akari Yamaya; Kento Sonoda; Tomomi Kawakita; Yuichi Koshiishi; Masashi Shingai; Misako Matsumoto; Tsukasa Seya
    International Immunopharmacology, 2025年06月
    英語, 研究論文(学術雑誌)
  • Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19
    Marumi Ohno; Toshiki Sekiya; Richard Obeng-Kyeremeh; Chimuka Handabile; Minori Haruta; Naoki Nomura; Tomomi Kawakita; Masashi Shingai; Hiroshi Kida
    Vaccine, 2025年05月
    英語, 研究論文(学術雑誌)
  • ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibody induction.
    Tomomi Kawakita; Toshiki Sekiya; Yayoi Kameda; Naoki Nomura; Marumi Ohno; Chimuka Handabile; Akari Yamaya; Hideo Fukuhara; Yuki Anraku; Shunsuke Kita; Shinsuke Toba; Hirotake Tsukamoto; Tomohiro Sawa; Hiroyuki Oshiumi; Yasushi Itoh; Katsumi Maenaka; Akihiko Sato; Hirofumi Sawa; Yasuhiko Suzuki; Lorena E Brown; David C Jackson; Hiroshi Kida; Misako Matsumoto; Tsukasa Seya; Masashi Shingai
    Journal of virology, e0229024, 2025年04月15日, [国際誌]
    英語, 研究論文(学術雑誌), UNLABELLED: ARNAX is a synthetic nucleotide-based Toll-like receptor 3 (TLR3) ligand that specifically stimulates the TLR3/TIR domain-containing adaptor molecule 1 (TICAM-1) pathway without activating inflammatory responses. ARNAX activates cellular immunity via cross-presentation; hence, its practical application has been demonstrated in cancer immunotherapy. Given the importance of cellular immunity in virus infections, ARNAX is expected to be a more effective vaccine adjuvant for virus infections than alum, an adjuvant approved for human use that mainly enhances humoral immunity. In the present study, the trimeric recombinant spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was prepared as a vaccine antigen and formulated with ARNAX. When T-cell and neutralizing antibody responses were evaluated in immunized mice, antigen formulated with ARNAX generated significantly larger numbers of antigenspecific CD4+ and CD8+ T cells, as well as higher titers of neutralizing antibodies, compared to antigen alone or antigen formulated with alum. In experiments where immunized mice were challenged with a SARS-CoV-2 mouse-adapted virus derived from the ancestral strain, immunization with antigen formulated with ARNAX reduced virus titers in the lungs at 3 days post-infection to a much greater extent than did immunization with either antigen alone or that formulated with alum. These results show that ARNAX potently enhances the levels of both cellular and humoral immunity above those seen with alum, providing significantly greater viral clearing responses. Thus, ARNAX may act as a useful adjuvant for prophylactic vaccines, particularly for viral infectious diseases. IMPORTANCE: Cellular immunity is a critical immunological defense system against virus infections. However, aluminum salts, the most widely used adjuvant for vaccines for human use, do not promote strong cellular immunity. To prepare for the next pandemic of viral origin, the development of Th1-type adjuvants with low adverse reactions that induce cellular immunity is necessary. ARNAX is a TLR3 agonist consisting of DNA-RNA hybrid nucleic acid, which is expected to be an adjuvant that induces cellular immunity. The present study using a coronavirus disease 2019 mouse model demonstrated that ARNAX potently induces cellular immunity in addition to humoral immunity with minimal induction of inflammatory cytokines. Therefore, ARNAX has the potential to be used as a potent and welltolerated adjuvant for vaccines against pandemic viruses emerging in the future.
  • Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.
    Chimuka Handabile; Marumi Ohno; Toshiki Sekiya; Naoki Nomura; Tomomi Kawakita; Mamiko Kawahara; Masafumi Endo; Tomohiro Nishimura; Minako Okumura; Shinsuke Toba; Michihito Sasaki; Yasuko Orba; Brendon Y Chua; Louise C Rowntree; Thi H O Nguyen; Masashi Shingai; Akihiko Sato; Hirofumi Sawa; Kazumasa Ogasawara; Katherine Kedzierska; Hiroshi Kida
    Scientific reports, 14, 1, 4204, 4204, 2024年02月20日, [国際誌]
    英語, 研究論文(学術雑誌), Due to the synchronous circulation of seasonal influenza viruses and severe acute respiratory coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), there is need for routine vaccination for both COVID-19 and influenza to reduce disease severity. Here, we prepared individual WPVs composed of formalin-inactivated SARS-CoV-2 WK 521 (Ancestral strain; Co WPV) or influenza virus [A/California/07/2009 (X-179A) (H1N1) pdm; Flu WPV] to produce a two-in-one Co/Flu WPV. Serum analysis from vaccinated mice revealed that a single dose of Co/Flu WPV induced antigen-specific neutralizing antibodies against both viruses, similar to those induced by either type of WPV alone. Following infection with either virus, mice vaccinated with Co/Flu WPV showed no weight loss, reduced pneumonia and viral titers in the lung, and lower gene expression of proinflammatory cytokines, as observed with individual WPV-vaccinated. Furthermore, a pentavalent vaccine (Co/qFlu WPV) comprising of Co WPV and quadrivalent influenza vaccine (qFlu WPV) was immunogenic and protected animals from severe COVID-19. These results suggest that a single dose of the two-in-one WPV provides efficient protection against SARS-CoV-2 and influenza virus infections with no evidence of vaccine interference in mice. We propose that concomitant vaccination with the two-in-one WPV can be useful for controlling both diseases.
  • Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire
    Masashi Shingai; Sayaka Iida; Naoko Kawai; Mamiko Kawahara; Toshiki Sekiya; Marumi Ohno; Naoki Nomura; Chimuka Handabile; Tomomi Kawakita; Ryosuke Omori; Junya Yamagishi; Kaori Sano; Akira Ainai; Tadaki Suzuki; Kazuo Ohnishi; Kimihito Ito; Hiroshi Kida
    Journal of Virology, American Society for Microbiology, 2024年02月07日
    研究論文(学術雑誌), As specific interactions between antigens and cell-surface antibodies trigger the proliferation of B-cell clones, the frequency of each antibody sequence in the samples reflects the size of each clonal population. Nevertheless, it is extremely difficult to extract antigen-specific antibody sequences from the comprehensive bulk antibody sequences obtained from blood samples due to repertoire bias influenced by exposure to dietary antigens and other infectious agents. This issue can be addressed by subtracting the background noise from the post-immunization or post-infection repertoire data. In the present study, we propose a method to quantify repertoire data from comprehensive repertoire data. This method allowed subtraction of the background repertoire, resulting in more accurate extraction of expanded antibody repertoires upon influenza virus infection. This accurate extraction of antigen- or infection-specific repertoire information is a useful tool for vaccine evaluation.
  • PGL-III, a Rare Intermediate of Mycobacterium leprae Phenolic Glycolipid Biosynthesis, Is a Potent Mincle Ligand.
    Shigenari Ishizuka; J Hessel M van Dijk; Tomomi Kawakita; Yuji Miyamoto; Yumi Maeda; Masamichi Goto; Guillaume Le Calvez; L Melanie Groot; Martin D Witte; Adriaan J Minnaard; Gijsbert A van der Marel; Manabu Ato; Masamichi Nagae; Jeroen D C Codée; Sho Yamasaki
    ACS central science, 9, 7, 1388, 1399, American Chemical Society ({ACS}), 2023年07月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination
    Tsukasa Seya; Masashi Shingai; Tomomi Kawakita; Misako Matsumoto
    Cells, 2023年05月29日
    研究論文(学術雑誌)
  • Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.
    Chimuka Handabile; Toshiki Sekiya; Naoki Nomura; Marumi Ohno; Tomomi Kawakita; Masashi Shingai; Hiroshi Kida
    Vaccines, 10, 5, 2022年05月19日, [国際誌]
    英語, 研究論文(学術雑誌), Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an alternative to the widely used split vaccine (SV) for the control of seasonal and pandemic influenza based on the superior priming potency of WPV to that of SV. In this study, we further examined and compared the immunological potency of monovalent WPV and SV of A/California/7/2009 (X-179A) (H1N1) pdm09 (CA/09) to generate immune responses against heterologous viruses, A/Singapore/GP1908/2015 (IVR-180) (H1N1) pdm09 (SG/15), and A/duck/Hokkaido/Vac-3/2007 (H5N1) (DH/07) in mice. Following challenge with a lethal dose of heterologous SG/15, lower virus titer in the lungs and milder weight loss were observed in WPV-vaccinated mice than in SV-vaccinated ones. To investigate the factors responsible for the differences in the protective effect against SG/15, the sera of vaccinated mice were analyzed by hemagglutination-inhibition (HI) and neuraminidase-inhibition (NI) assays to evaluate the antibodies induced against viral hemagglutinin (HA) and neuraminidase (NA), respectively. While the two vaccines induced similar levels of HI antibodies against SG/15 after the second vaccination, only WPV-vaccinated mice induced significantly higher titers of NI antibodies against the strain. Furthermore, given the significant elevation of NI antibody titers against DH/07, an H5N1 avian influenza virus, WPV was also demonstrated to induce NA-inhibiting antibodies that recognize NA of divergent strains. This could be explained by the higher conservation of epitopes of NA among strains than for HA. Taking these findings together, NA-specific antibodies induced by WPV may have contributed to better protection from infection with heterologous influenza virus SG/15, compared with SV. The present results indicate that WPV is an effective vaccine for inducing antibodies against both HA and NA of heterologous viruses and may be a useful vaccine to conquer vaccine strain mismatch.
  • Point mutation in the stop codon of MAV_RS14660 increases the growth rate of Mycobacterium avium subspecies hominissuis.
    Tomomi Kawakita; Tetsu Mukai; Mitsunori Yoshida; Hiroyuki Yamada; Masaaki Nakayama; Yuji Miyamoto; Masato Suzuki; Noboru Nakata; Takemasa Takii; Akihide Ryo; Naoya Ohara; Manabu Ato
    Microbiology (Reading, England), 167, 2, 2021年02月, [国際誌]
    英語, 研究論文(学術雑誌), Mycobacterium avium subspecies hominissuis (MAH) is a pathogen that causes various non-tuberculous mycobacterial diseases in humans and animals worldwide. Among the genus, MAH is characterized by relatively slow growth. Here, we isolated a rapidly growing variant of the MAH 104 strain. The variant strain (named N104) exhibited an enhanced growth rate and higher motility compared to the parent MAH 104 strain (P104). Whole-genome sequencing analysis of N104 revealed the loss of the stop codon of MAV_RS14660 due to a single nucleotide replacement, resulting in the substitution of the codon for tryptophan. Notably, exclusion of the stop codon ligated the open reading frames and caused the fusion of two adjacent proteins. A revertant parent strain, in which a mutation was introduced to restore the stop codon, revealed that elimination of the stop codon in MAV_RS14660 was responsible for the N104 phenotype. Furthermore, we analysed the phenotypes of the parent and mutated strains by determining the functions of the MAV_RS14660 and MAV_RS14655 coding regions flanking the stop codon. The mutant strains, expected to express a fusion protein, exhibited increased resistance to antimicrobial drugs and exogenous copper toxicity compared to that of the parent strains. These findings suggest that the fusion of the MAV_RS14660- and MAV_RS14655-encoding regions in the mutant N104 strain could be related to the modified functions of these intrinsic proteins.
■ その他活動・業績
  • 急速に増殖するMycobacterium aviumの亜種のhominissuis 104株の分析(Analysis of a rapid growing Mycobacterium avium subspecies hominissuis 104 strain)
    河喜多 智美; 吉田 光範; 鈴木 仁人; 中田 登; 瀧井 猛将; 中山 真彰; 梁 明秀; 星野 仁彦; 阿戸 学; 大原 直也, 日本細菌学雑誌, 74, 1, 61, 61, 2019年03月
    日本細菌学会, 英語
■ 共同研究・競争的資金等の研究課題
  • MAC症に対する新規TLR3アゴニストARNAXの治療効果の検証
    科学研究費助成事業
    2023年04月01日 - 2027年03月31日
    河喜多 智美
    Mycobacterium avium complex(MAC)は宿主免疫から逃れ、難治性慢性感染を引き起こす。Toll-like receptor (TLR)のアゴニストは、免疫不活化剤として、MAC症の補助的治療効果を示すことが期待されている。本研究では、 新規TLR3アゴニストであるARNAXのMAC症に対する投与効果をマウスモデルで検討する。
    本年度は、代表的なMAC症の起炎菌であるMycobacterium avium subsp. hominissuis (MAH)の臨床分離株を用いて、MAC感染マウスモデルの作製を行った。0.5-5×10^7 CFUをC57BL/6マウスに腹腔内接種または経気道接種し、肺、脾臓および肝臓における菌量の変化と肉芽腫様病変の形成を感染9週目まで評価した。
    腹腔内接種では、各臓器より検出される菌量は感染3週から6週で増加し、6週から9週で安定する傾向が認められた。明らかな肉芽種様病変は感染6週以降の肝臓から確認された。菌を貪食したマクロファージの集塊を含む病変は、脾臓では感染3週後、肺では6週以降で顕著であった。経気道接種による感染では、肺全体に亘って強い炎症と菌体が観察され、菌量も感染9週目まで高い値を示した。脾臓および肝臓でも明らかな病変部を認め、肝臓では感染6週以降で肉芽腫様病変が観察された。
    今後はこれらを指標に、ARNAXの投与効果を検討する。
    日本学術振興会, 若手研究, 北海道大学, 23K15362